NCT02874144View on ClinicalTrials.gov

Anti-Inflammatory Agent in Sinusitis

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 20, 2016

Primary Completion Date

January 7, 2020

Study Completion Date

August 10, 2020

Conditions
Nasal Polyps
Interventions
DRUG

AZ compound

40 mg three times daily po for 12 weeks

OTHER

Collection of Biological Specimens

collection of biomarkers for analysis of nasal disease

DRUG

Intranasal corticosteroid

QD Nasal Spray

DRUG

Placebo

looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks

All Listed Sponsors
lead

Northwestern University

OTHER

NCT02874144 - Anti-Inflammatory Agent in Sinusitis | Biotech Hunter | Biotech Hunter